TY - JOUR
T1 - The chemosensitivity of nodal metastases in recurrent epithelial ovarian cancer
AU - Kataoka, F.
AU - Tsuda, H.
AU - Nomura, H.
AU - Chiyoda, T.
AU - Tominaga, E.
AU - Suzuki, A.
AU - Susumu, N.
AU - Aoki, D.
PY - 2011/5/11
Y1 - 2011/5/11
N2 - Purpose: In this study, we compared second-line chemotherapy effects of nodal metastases with other metastases sites. Methods: The medical records of 44 women with recurrent ovarian cancer who received second-line chemotherapy were retrospectively reviewed. Results: Median age at the time of second-line chemotherapy was 55 years (range: 31-74). Recurrent sites were as follows: 29 patients had a solitary site (abdominal cavity: 8; lymph node: 3; pelvic cavity: 10; liver: 4; lung: 4) and 15 patients had multiple sites In total, the response rate was 30% (CR: 8, PR: 5). The response rate in sensitive cases was higher than in refractory/resistant cases (50% vs 5% p = 0.002). However, age, chemotherapy regimen, histologic type and number of diseases were not related with chemotherapy effect. In all diseases, response rate tended to be higher in lymph node disease than in the others (44% vs 27%). In both sensitive and refractory/resistant cases, response rate tended to be higher in lymph node disease. Conclusion: The response rate for lymph node diseases tended to be relatively high. Further study analyzing survival will be required to conclude the chemotherapy effect.
AB - Purpose: In this study, we compared second-line chemotherapy effects of nodal metastases with other metastases sites. Methods: The medical records of 44 women with recurrent ovarian cancer who received second-line chemotherapy were retrospectively reviewed. Results: Median age at the time of second-line chemotherapy was 55 years (range: 31-74). Recurrent sites were as follows: 29 patients had a solitary site (abdominal cavity: 8; lymph node: 3; pelvic cavity: 10; liver: 4; lung: 4) and 15 patients had multiple sites In total, the response rate was 30% (CR: 8, PR: 5). The response rate in sensitive cases was higher than in refractory/resistant cases (50% vs 5% p = 0.002). However, age, chemotherapy regimen, histologic type and number of diseases were not related with chemotherapy effect. In all diseases, response rate tended to be higher in lymph node disease than in the others (44% vs 27%). In both sensitive and refractory/resistant cases, response rate tended to be higher in lymph node disease. Conclusion: The response rate for lymph node diseases tended to be relatively high. Further study analyzing survival will be required to conclude the chemotherapy effect.
KW - Lymph node
KW - Recurrence
KW - Recurrent site
KW - Second-line chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=79955680556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955680556&partnerID=8YFLogxK
M3 - Article
C2 - 21614904
AN - SCOPUS:79955680556
VL - 32
SP - 160
EP - 163
JO - European Journal of Gynaecological Oncology
JF - European Journal of Gynaecological Oncology
SN - 0392-2936
IS - 2
ER -